title: Treatment outcome of acute promyelocytic leukemia with modified aida protocol.
abstract: We analyzed the outcome of a series of 19 newly diagnosed patients with acute promyelocytic leukemia treated with AIDA modified protocol, using mitoxantrone in place of idarubicin. Eleven patients achieved morphologic CR (58%). The remaining 8 patients had induction failure due to death during induction. Ten of eleven patients in CR achieved molecular remission after induction therapy and all the 8 patients had molecular remission after consolidation. Eight patients completed the three consolidation courses as scheduled and then proceeded to maintenance therapy. After a median follow up of 52 months, no molecular or hematological relapse has occurred. The 4-year disease-free survival is 82%. The study showed the antileukemic efficacy of mitoxantrone and that it could be used as a reasonable option in anthracycline-based strategies in APL.
authors.affiliation: Hematology and Hemotherapy Center, University of Campinas, SP, Rua Carlos Chagas 480, Campinas 13083-970, Brazil.
authors.forename: Kátia B Barbosa
authors.initials: KB
authors.lastname: Pagnano
authors.forename: Gustavo
authors.initials: G
authors.lastname: de Carvalho Duarte
authors.forename: Irene
authors.initials: I
authors.lastname: Lorand-Metze
authors.forename: Márcia Torresan
authors.initials: MT
authors.lastname: Delamain
authors.forename: Eliana Cristina
authors.initials: EC
authors.lastname: Miranda
authors.forename: Cármino Antonio
authors.initials: CA
authors.lastname: De Souza